Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.

Abstract

We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2-week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicity-related symptoms. Cystoscopic follow-up showed a gradual decline in the presence of tumor to a complete response rate of 87.1% at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.

• Authors: A Pavlotsky, A Eidelman, F Barak, H Alon, Y Horn
• Journal: Journal of surgical oncology (J Surg Oncol) Vol. 41 Issue 1 Pg. 9-11 (May 1989) ISSN: 0022-4790 [Print] United States
• PMID: 2497274 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Mitomycins
• Mitomycin

Topics

• Administration, Intravesical
• Adult
• Aged
• Aged, 80 and over
• Carcinoma, Transitional Cell (drug therapy)
• Clinical Trials as Topic
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Mitomycin
• Mitomycins (administration & dosage, therapeutic use)
• Neoplasm Recurrence, Local (drug therapy)
• Urinary Bladder Neoplasms (drug therapy)